[Skip to content]

EPDA - European Parkinsons Disease Association EPDA - European Parkinsons Disease Association EPDA - European Parkinsons Disease Association EPDA - European Parkinsons Disease Association EPDA - European Parkinsons Disease Association EPDA - European Parkinsons Disease Association EPDA - European Parkinsons Disease Association
EPDA - European Parkinsons Disease Association
REWRITE TOMORROW
.

Speech and language therapy and Parkinson’s

What is speech and language therapy?

Speech and language therapists help people communicate to the best of their ability by assessing and treating speech, language and communication problems. They also treat people who have eating, swallowing and drooling problems.

Ways in which the therapist can help include:

  • providing exercises to improve communication on a one-to-one basis, or in a group
  • advising on specific communication difficulties
  • suggesting breathing and postural techniques to facilitate better voice and overall communication
  • offering tips and strategies to make particular activities easier, such as talking on the telephone
  • recommending special tools and equipment to aid communication
  • assessing and treating difficulties with eating, drooling and swallowing
  • advising carers.

Speech and language therapists can be based in both hospital and community settings. When treating people with Parkinson’s, they tend to work alongside other healthcare professionals as part of a multidisciplinary team. They are also involved with a growing number of initiatives that work on voice in a group setting such as "Quivers and Quavers"1, an exciting voice therapy project in the UK.


Did you know?

According to the Royal College of Speech and Language Therapists, around 2.5 million people in the UK have a communication difficulty.

 


References


  1. Quivers and Quavers: an innovative voice therapy group for people with Parkinson's. European Parkinson's Nurses Network (EPNN) Journal 2008; 12: 16-17

 


Acknowledgement


We would like to thank the following for their contributions to this information:

  • Julia Johnson and Phil Maillard, Regional Neurosciences Centre, King’s College Hospital, London & Clinical Advisor on Progressive Neurological Disease, Royal College of Speech and Language Therapists, London

We would like to acknowledge the following source(s) in compiling this information:

EPDA EPDA EPDA EPDA EPDA EPDA EPDA EPDA